ArticleImmunology1993
Immunolocalization and characterization of the rat analogue of human CD59 in kidney and glomerular cells.
Article in Immunology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Urine complement analysis implies complement activation is involved in membranous nephropathy.Frontiers in medicine · 2025Article
- Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells.Infection and immunity · 2013Article
- Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison.Immunology · 2003Article
- Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.The Biochemical journal · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
CD59, a potent inhibitor of the human membrane attack complex (MAC) of complement, is present on many different tissues throughout the body. Recently we identified and characterized the rat analogue of CD59 and produced a number of monoclonal antibodies (mAb). We have now used these antibodies to demonstrate, by immunofluorescence microscopy, that rat CD59 was widely expressed in the rat kidney. Staining of renal sections revealed the presence of rat CD59 in abundance in the glomerulus, collecting ducts and distal tubules. Staining was abolished by treatment of sections with phosphatidylinositol-specific phospholipase C (PIPLC). Rat mesangial cells also stained strongly for rat CD59, giving an intensely granular staining pattern. In complement attack experiments the cultured mesangial cells were rendered more susceptible to lysis by rat or human complement after preincubation with the anti-inhibitor mAb. The results demonstrate that the rat analogue of CD59 is present and functionally active in rat renal tissue. The protective effect of CD59 against MAC-mediated tissue injury can now be examined in rat models of human renal disease.
Indexed as
Identifiers
7507093PMC1422212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.